Patients with systemic lupus erythematosus (SLE) display increased numbers of immature neutrophils in the blood, but the exact role of these immature neutrophils is unclear. Neutrophils that sediment within the peripheral blood mononuclear cell fraction after density centrifugation of blood are generally defined as low-density neutrophils (LDNs). Far beyond antimicrobial functions, LDNs are emerging as decision-shapers during innate and adaptive immune responses. Traditionally, neutrophils have been viewed as a homogeneous population. However, the various LDN populations identified in SLE to date are heterogeneously composed of mixed populations of activated mature neutrophils and immature neutrophils at various stages of differentiation. Controversy also surrounds the role of LDNs in SLE in terms of whether they are proinflammatory or polymorphonuclear myeloid-derived suppressor cells. It is clear that LDNs in SLE can secrete increased levels of type I interferon (IFN) and that they contribute to the cycle of inflammation and tissue damage. They readily form neutrophil extracellular traps, exposing modified autoantigens and oxidized mitochondrial DNA, which contribute to autoantibody production and type I IFN signaling, respectively. Importantly, the ability of LDNs in SLE to perform canonical neutrophil functions is polarized, based on mature CD10+ and immature CD10− neutrophils. Although this field is still relatively new, multiomic approaches have advanced our understanding of the diverse origins, phenotype, and function of LDNs in SLE. This review updates the literature on the origin and nature of LDNs, their distinctive features, and their biologic roles in the immunopathogenesis and end-organ damage in SLE.

Traditional concepts of SLE immunopathogenesis

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology. Its incidence has been constant in recent decades, with ~4–5 per 100,000 people affected each year and a female: male bias peaking at 9:1 in adulthood (1,2). However, the severity and mortality are higher in childhood-onset and male SLE (3). It is one of the most common systemic autoimmune diseases, with a prevalence of 40–100 per 100,000 people in the US (4,5). Common hypotheses about SLE immunopathogenesis suggest that environmental triggers, such as infectious agents, operate in the context of genetic and epigenetic influences, resulting in aberrations in antigen presentation, lymphoid signaling, apoptosis, epitope modification, and antigen and immune complex (IC) clearance (6,7). Ordinarily, SLE is a polygenic disease, with >50 lupus susceptibility loci now identified (8,9). Risk and severity are also associated with an increasing number and additive effect of susceptibility alleles (10). Given that SLE is an immunologic disease, it is not surprising that the top genetic associations with disease are those associated with immunity, including the HLA genes IRF5, IRF7, IRAK1, TNFAIP3, TNIP1, IFIH1, TYK2, and C1Q (11).

Traditionally, SLE has been considered a disease of perturbed adaptive immunity, due to the critical pathogenic roles of B cells and T cells (12,13). Characteristic antinuclear antibodies (ANAs), such as anti–double-stranded DNA, anti-RNA, and anti-RNA–associated proteins, are produced by autoreactive B cells through both extrafollicular pathways and germinal center reactions (14,15). These ANAs form ICs with nuclear material released following excessive or inappropriate cell death processes. The subsequent IC deposition in tissues results in a proinflammatory loop, which involves the recruitment of multiple immune cells with cytokine release and the destruction of multiple organs (16,17).
Type I interferons (IFNs) comprise a family of cytokines that have been associated with SLE. They are divided into 5 classes (IFNα, IFNβ, IFNε, IFNκ, and IFNω), with IFNα being further categorized into 12 subtypes (18). IFNα was first described in the peripheral blood of SLE patients by Preble et al in 1982 (19). Since then, an “IFN signature” has been identified in the peripheral blood mononuclear cells (PBMCs) of SLE patients (20,21).

This up-regulation of IFN-regulated genes occurs in a subset of adult SLE patients and may reflect differences in genetics, environmental triggers, or disease severity (21). It is also now clear that although IFNα subtypes are important in SLE, additional type I IFNs, such as IFNβ and IFNκ, play key roles in disease (18,22,23). This interest in type I IFNs initiated a plethora of clinical trials with therapeutic targets directed at IFNα and type I IFN receptor, which have more recently been redirected toward those expressing the IFN signature (24). Neutrophils have generated interest for their role in the production of type I IFNs and for their proinflammatory and antiinflammatory functions in SLE (21,25–27). Moreover, there is a burgeoning number of reports showing that they play an integral role in disease pathogenesis.

**Neutrophil fundamentals**

To understand dysfunction of any cell type, it is necessary to understand the underlying biology. Neutrophils are the most abundant immune cell type in the human peripheral blood, acting as the first responders during sterile and microbial insults (28). Chemotaxis and extravasation toward the potential pathogen are mediated through the activation of a number of surface receptors, including selectins and integrins, chemokine receptors, Fcγ receptors (FcγRs), and ILiMP receptors. Neutrophils target microorganisms through the generation of reactive oxygen species (ROS) via respiratory burst, the release of bactericidal enzymes through degranulation, and phagocytosis, a process that engulfs the potentially pathogenic organism (26,29,30). More recently, NETosis has been described as a mechanism to trap potential pathogens within a network of expelled cell contents termed neutrophil extracellular traps (NETs) (29). Neutrophils also play a key role in eliminating opsonized bacteria and in antibody-dependent cell-mediated cytotoxicity (31,32). They constitutively express a low-affinity IgG receptor, FcγRlla (CD32A) and the glycosyl phosphatidylinositol-linked FcγRllb (CD16B), which serves as a coreceptor (33,34). Upon the crosslinking of FcγR in vitro, neutrophils activate, degranulate, produce ROS, and can trigger NETosis (33). In addition, neutrophils interact with the complement pathway to ensure clearance of invading pathogens, primarily through C5a (35).

The in vivo half-life of human circulating neutrophils is 19–90 hours. This estimate is derived from the ratio of the number of neutrophils in the blood to the number of mitotic neutrophil precursors in the bone marrow (36,37). Consistent with this relatively short lifespan, 50% of the bone marrow is devoted to neutrophil production, releasing ~5–10 × 10¹¹ cells per day, which increases during an infection (38,39). This lifespan increases following exposure to cytokines or other proinflammatory agents present in infected or inflamed tissue (40,41).

Neutrophil heterogeneity is an important feature of immune pathophysiology, and therefore strategies for assessing neutrophil subsets based on their maturation have been proposed (28,30). Maturation from committed proliferative neutrophil precursors (pre-neutrophils) into nonproliferative immature neutrophils and then mature neutrophils can be detected, using changes in cell surface molecules (28,30).

**Low-density neutrophils in SLE**

In 1986, Hacbarth and Kajdacsy-Balla were the first to describe the presence of “low buoyant density neutrophils” in the peripheral blood mononuclear cell (PBMC) preparations obtained from adult SLE patients (42) (Figure 1). This preparation remains common and involves the centrifugation of whole blood, mixed with media, layered over a polysaccharide or silica gradient with a density of ~1.077 gm/ml (e.g., Ficoll-Paque, Histopaque-1077, Percoll) for humans (43). Due to their relative high density, neutrophils end up below the Ficoll layer, on top of the erythrocyte fraction (often termed high-density neutrophils [HDNs]). The PBMC fraction is found in the interphase between the Ficoll layer and the plasma (43). In this original study, the authors hypothesized that humoral factors in patient plasma induced activation of the neutrophils in vitro, causing degranulation and decreasing their buoyant density, leaving them to settle with the PBMCs as low-density neutrophils (LDNs) (42). Supporting this idea, stimulation of whole blood with fMLP was shown to lead to an increase in the percentage of LDNs at the PBMC fraction in a dose-dependent manner, representing up to 12.5% of the population (44,45). Furthermore, the activation of neutrophils led to increased expression of CD66b, which is mobilized from intracellular granules to the cell membrane during degranulation, possibly contributing to the LDN increase (45).

In 2003, Bennett et al performed microarray analysis of PBMCs from pediatric SLE patients and identified high expression of neutrophil-specific genes (20). This “granulocyte signature” was due to an increase of LDNs in the PBMC layer (20). This signature was not caused by steroid treatment as it was demonstrated in several newly diagnosed, untreated pediatric SLE patients (20). Moreover, intravenous pulse high-dose glucocorticoid treatment extinguished the IFN signature without affecting the granulocyte signature in pediatric SLE PBMCs (20).

Among low-density granulocytes, which encompass neutrophils, eosinophils, and basophils (26,43), only LDNs have been described in SLE. The frequency of LDNs found contaminating the PBMC fraction is significantly higher in SLE patients, at ~17% of total PBMCs, compared to ~5% in healthy donor PBMCs (26,46,47) (Table 1). Neutrophils with low-density features have also been described in other rheumatic diseases such as antineutrophil
cytoplasmic antibody–associated vasculitis, myositis, primary antiphospholipid syndrome, and psoriasis (48–53). In summary, LDNs form a contaminating granulocytic population in the PBMC layer of fractionated blood, which is increased in SLE.

SLE LDN surface markers, nuclear morphology, and activation markers. LDNs can be distinguished from monocytes in the PBMC layer by their high granularity and expression of surface molecules using flow cytometry (20,26,47) (Table 1). LDNs also lack major histocompatibility complex class II and the costimulatory molecule CD86 (B7.2), in contrast to monocytes, and express CD15, CD16b (FcγIIIb), CD33, and CD11b (Table 1). Comparatively, SLE LDNs express higher levels of the activation markers CD11b, CD66b, CD63, and CD107a, relative to autologous HDNs (26,47). CD11c, CD31, granulocyte colony-stimulating factor (G-CSF) receptor, and granulocyte–macrophage colony-stimulating factor receptor have also been found on their surface, in contrast to HDNs (54,55). However, they do not differ with regard to surface L-selectin (CD62L), which is a sensitive measure of activation (26).

More recently, 2 subpopulations of SLE LDNs which comprise immature CD10− and mature CD10+ neutrophils have been identified (46,56) (Table 1). Similarly, morphologic analysis of SLE LDNs shows all stages of neutrophil development, including promyelocytes, myelocytes, metamyelocytes, bands, and segmented neutrophils (20,46,54,56) (Table 1). Moreover, up to 60% of human SLE LDNs are mature, in contrast to HDNs, which consist of >90% mature cells (26,54).
of mature cells, together with immature and activated/regulatory populations.

**Cytokine profiles of SLE LDNs.** Resting healthy donor HDNs, SLE HDNs, and LDNs show similar levels of cytokine release (26). However, phorbol myristate acetate–stimulated SLE LDNs secrete more tumor necrosis factor (TNF) and have higher levels of IFNα mRNA compared to autologous SLE and healthy donor HDNs (26) (Table 1). Furthermore, cultured supernatants from resting or stimulated SLE LDNs induce type I IFN–inducible genes, in contrast to HDNs from SLE patients or healthy donors, suggesting that they release Toll-like receptor (TLR) ligands and/or IFNα itself (26). Although plasmacytoid dendritic cells provide the highest levels of IFNα upon stimulation, all other nucleated cells have the capacity to produce IFNα (25,61). SLE LDN supernatants also induce IFNγ, TNF, and lymphoxygen α (LTA) from T cells, suggesting a proinflammatory phenotype of LDNs (47). However, more research is required to fully comprehend the capacity of LDNs in cytokine production.

**SLE LDNs show a propensity for NETosis rather than phagocytosis.** LDNs from SLE patients have a lower capacity for phagocytosis compared to autologous HDNs from SLE patients or healthy donors (26) (Table 1). This may be due to the relatively high proportion of immature cells, since CD10− SLE LDNs are less effective at phagocytosis compared to mature CD10+ SLE LDNs (56). Findings from a study by Lood et al suggest that this reduction may be due to an increase in the cleavage of FcγRIIA following activation by TLR-7/8 ligands (62). In contrast, SLE LDNs show an increase in spontaneous NETosis and the release of self-reactive material compared to autologous and healthy donor HDNs (27,60,63). Enhanced NETosis also results in comparatively higher secretions of interleukin-17 (IL-17), an important cytokine associated with T cell activation, particularly in autoimmunity (60,64) (Table 1). The NETosis in SLE LDNs is, in part, due to an increase in mitochondrial ROS (mtROS) release (27,65) (Figure 1 and Table 1). Importantly, mtROS production is sufficient for the generation of NETs even in the absence of functional NADPH oxidase (27). The oxidized mitochondrial DNA (mtDNA) derived from the LDN NETs is proinflammatory, activating stimulator of IFN genes to induce type I IFN signaling in target cells (27). Interestingly, mitochondrial stress alone can induce the release of mtDNA and induce IFN signaling. Inhibition of this process decreases NET formation and mtDNA release, reducing lupus-like disease in a model system (66).

Additional cytokines, ligands, and pathways associated with NETosis have also been described in the pathogenesis of SLE. Lipopolysaccharide was described early on in the literature as a major stimulant of NETosis. However, in the absence of a bacterial infection, the specific stimulus in SLE remains unclear. IL-18 has been shown as an effective stimulus of NET release by SLE LDNs in active lupus nephritis (67,68). Lood et al have

### Table 1. Biologic and clinical characteristics of LDNs in SLE*

| Prevalence, % | HD 0.81–5.00; SLE 2.37–17.00 |
|-------------|-------------------------------|
| Morphology  | Promyelocytes, myelocytes, metamyelocytes, bands, and segmented neutrophils |
| Immunophenotype | All LDNs CD3−CD19−CD20−CD56− and CD11b+CD14+CD15+CD16+CD33+CD66b−; mature LDNs CD10−; immature LDNs CD10− |
| Functional properties | Increased TNF, IFNγ, IL-17+ NETs; decreased phagocytosis; decreased chemotactic activity; increased mtROS production; increased spontaneous NETosis with NET-mtDNA release |
| Homeostatic/pathologic relevance | CD10+ LDNs associated with noncalcified plaque burden severity, vascular inflammation, and lower HDL cholesterol efflux capacity in SLE patients; and negatively correlated with renal function in white SLE patients; CD10− LDNs positively correlated with proteinuria in white SLE patients |

*LDNs = low-density neutrophils; SLE = systemic lupus erythematosus; HD = healthy donors; TNF = tumor necrosis factor; IFNα = interferon-α; IL-17 = interleukin-17; NETs = neutrophil extracellular traps; mtROS = mitochondrial reactive oxygen species; mtDNA = mitochondrial DNA; HDL = high-density lipoprotein.

**Genetics, epigenetics, and gene expression of SLE LDNs.** Analyses of genomic instability have shown increased copy number alterations and microsatellite instability in SLE LDNs compared to matched HDNs from the same individuals (8). These somatic alterations are consistent with the notion of DNA strand break repair and a replication error–prone status, supporting a model whereby genomic damage contributes to the development of an abnormal population of neutrophils (8). Consistent with these findings, chronically elevated ROS, which often occurs in SLE, affects several aspects of DNA damage response and may lead to accumulation of such genomic changes (57,58). An assessment of epigenetic accessibility by Coit et al also revealed a robust and consistent demethylation of IFN signature genes in SLE LDNs and HDNs compared to healthy donor HDNs (59).

A more stratified transposase-accessible chromatin sequencing study by Mistry et al has shown that immature SLE LDNs have more open peaks compared to mature SLE LDNs associated with noncalcified plaque burden severity, vascular inflammation, and lower HDL cholesterol efflux capacity in SLE patients; and negatively correlated with renal function in white SLE patients (60). Interestingly, type I IFN signaling transcripts, which include MX1, IFIT3, IFI44, and RSD2, are increased only in mature CD10+ SLE LDNs and not in the immature CD10− population (54,56). However, this may simply reflect the expression time to the inflammatory milieu. Taken together, these data suggest that LDNs may be a mixed cell population consisting...
also demonstrated that RNP-containing ICs can induce mitochondria mobilization, mtROS production, and the release of oxidized mtDNA (27). Similarly, van Dam et al demonstrated that SLE ICs are able to induce nonlytic NETosis in healthy donor HDNs via FcγR signaling, with rapid extrusion of NETs enriched with oxidized mtDNA (69). Therefore, ICs, mitochondrial dysfunction, and cytokines may all contribute to increased NETosis in SLE LDNs.

SLE LDNs and myeloid-derived suppressor cells are distinct cell types

In 2007, Gabrilovic et al suggested the term “myeloid-derived suppressor cells” (MDSCs), informed by the myeloid origin, immunosuppressive function, and systemic expansion of these cells in a cancer-related context (70). MDSCs consist of 2 large groups of cells: polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs) (71). PMN-MDSCs are phenotypically and morphologically similar to neutrophils, while M-MDSCs are similar to monocytes (71). Traditionally, PMN-MDSCs are enriched in the low-density PBMC fraction using density centrifugation methods, in a similar manner to LDNs (71). PMN-MDSCs and SLE LDNs also express similar surface molecules, including CD11b+CD14−CD15+CD66b+, leading to a hypothesis that they are the same type of cells (26,46,70) (Table 2). However, an evaluation of the literature on PMN-MDSCs, primarily from cancer research, and SLE LDNs also reveals differences between the neutrophil groups (Table 2). The lectin-like oxidized low-density lipoprotein receptor 1 was identified to distinguish PMN-MDSCs from other neutrophils, although it is expressed on only one-third of PMN-MDSCs in cancer patients (72). Furthermore, it is expressed on LDNs from healthy donors and SLE patients at similar levels (47), eliminating its role in categorization.

The hallmark of PMN-MDSCs is their ability to suppress T cell function (72), which is contrary to findings from LDN studies in SLE (Table 2). Cultured SLE LDNs, or their supernatants, fail to suppress proliferation of activated healthy donor naive CD4+ T cells (47). Moreover, the addition of SLE LDNs enhances the production of IFNγ, TNF, and LTα by stimulated CD4+ T cells (47). This may be due to the comparative heterogeneous nature of SLE LDNs discussed above. The addition of predominantly immature CD10− SLE LDNs enhances T cell proliferation in vitro; however, isolated CD10+ LDNs can promote immunosuppression via a CD18-mediated contact-dependent arginase 1 release (46). Similarly, studies on immature CD10− LDNs from donors receiving recombinant human G-CSF show increased T cell proliferation and IFNγ production (46), suggesting that maturity is a key factor in suppressive function. In contrast to SLE LDNs, morphologic examinations of PMN-MDSCs in cancer patients showed segmented cells, and therefore maturity, in 8 of 9 studies (43). It is currently unknown whether LDNs from pediatric SLE patients are suppressive or proinflammatory.

Programmed death ligand 1 (PD-L1) is expressed in MDSCs, and this may contribute to the success of recent anti–PD-L1 immunotherapies used in cancer (70) (Table 2). Inhibition of this suppressive receptor, particularly on T cells, results in increased activation of the immune system and elimination of tumor cells. On

| Table 2. | Phenotypic, biochemical, molecular, and functional properties of SLE LDNs and PMN-MDSCs* |
|----------|------------------------------------------------------------------------------------------|
| Physical characteristic | SLE LDNs | PMN-MDSCs |
| Density | Low | Low |
| Promorphology | Promyelocytes, myelocytes, metamyelocytes, bands and segmented neutrophils | Metamyelocytes, bands, and segmented neutrophils |
| Surface marker | | |
| FSC | NA | High |
| CD11b | +++ | ++ |
| CD14 | −/+ | − |
| CD15 | +++ | +++ |
| CD66b | +++ | +++ |
| LOX-1 | +/++++ | + |
| Biomarker | | |
| ROS | + | +++ |
| ARG1 | ++ | + |
| PD-L1 | + | + |
| Immunometabolic status | | |
| ER stress | ++ | ++ |
| Functional test | | |
| Inhibition of T cell proliferation | No | Yes |
| Inhibition of IFNγ production | No | Yes |

* Positive and negative signs indicate the level of expression of relevant markers in SLE LDNs or polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). NA = not applicable; LOX-1 = lectin-like oxidized low-density lipoprotein receptor 1; ROS = reactive oxygen species; ARG1 = arginase 1; PD-L1 = programmed death ligand 1; ER = endoplasmic reticulum (see Table 1 for other definitions).
MDSCs, inhibition of PD-L1 may reduce their suppressive action. Interestingly, PD-L1 has also been detected in LDNs from SLE patients (47). Further research is necessary to determine whether activating PD-L1 will be an effective novel therapy in SLE through its suppression of the immune system.

**LDNs are associated with organ damage in SLE**

**LDNs and premature cardiovascular disease.** Cardiovascular disease (CVD) accounts for more than one-third of all deaths in SLE patients (73). This is due to a plethora of factors, including autoantibodies, systemic inflammation, and endothelial injury, in addition to traditional CVD risk factors (74). A longer disease duration, higher damage index, and less aggressive immunosuppression are associated with increased heart disease, suggesting that immune dysregulation contributes to plaque progression and vascular complications, which are essential factors associated with CVD (73).

Endothelial dysfunction is an early central phase in the evolution of atherosclerosis and has been described as the intermediate link between CVD risk factors and the development of atherosclerosis (75). SLE LDNs have been associated with endothelial damage and abnormal endothelial proliferation in vitro (54). Furthermore, the reduced ability of SLE endothelial progenitor cells to differentiate into mature endothelial cells is mediated in part by IFNα produced by CD10+ SLE LDNs (26). Mature CD10+ LDNs have also been associated with noncalcified plaque burden severity and lower high-density lipoprotein (HDL) cholesterol efflux capacity in SLE patients (56,76) (Table 1). HDL cholesterol efflux capacity is the ability of HDL to promote efflux of cholesterol from macrophages and has a strong inverse correlation with CVD (77). In support of these findings, SLE LDNs have higher levels of genes associated with the regulation of vascular inflammation and noncalcified plaque burden, including AZU1, IMO, CTSG, PRTN3, ELANE, and DEFA3, compared to healthy donors (76) (Table 1).

In vitro culture of SLE LDNs with human umbilical vein endothelial cells results in increased endothelial cytotoxicity compared to autologous or healthy donor HDNs (26,60). This cytotoxicity is dependent on NET formation and the externalization and activation of matrix metalloproteinases (26,60). In support of these findings, administration of a potent antioxidant and ROS inhibitor, 2D3 decreases NETosis in spontaneous NETosis in SLE LDNs in vitro.

### Table 3. Potential therapies targeting LDNs or NET formation in SLE*

| Drug                   | Mechanism of action                        | Effect on neutrophils/NETs                                                                 | Effect on disease/clinical use                                                                 |
|------------------------|--------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Chloroquine/           | Unknown                                    | Chloroquine inhibits NETosis in SLE LDNs in vitro                                        | Antimalarials used as first-line treatment in SLE                                            |
| hydroxychloroquine     |                                            |                                                                                          |                                                                                                |
| Colchicine             | Possibly via inhibition of tubulin          | Inhibits spontaneous NETosis in Behçet’s syndrome HDNs in vitro                           | Used to treat SLE pericarditis                                                                |
|                       | polymerization                             |                                                                                          |                                                                                                |
| Cyclosporine           | Modulates calcium-dependent                | Inhibits ionomycin- and IL-8–induced NETosis in healthy donor HDNs in vitro              | Used to treat membranous lupus nephritis                                                       |
|                       | signal transduction by calcineurin          |                                                                                          |                                                                                                |
|                       | inhibition                                 |                                                                                          |                                                                                                |
| DNase I                | Enzymatic degradation of DNA                | Enzymatic degradation of NET-DNA                                                          | Well tolerated in phase I study in 17 patients with lupus nephritis                            |
| Eculizumab             | Monoclonal antibody against                | ANCA-induced NETosis in C5a-promoted healthy donor HDNs in vitro                         | Used to treat SLE patients with thrombotic microangiopathy                                   |
|                       | complement C5 to inhibit the cleavage of   |                                                                                          |                                                                                                |
|                       | C5 to C5a and C5b, possibly via reduction  |                                                                                          |                                                                                                |
|                       | of C5a-promoted neutrophils for            |                                                                                          |                                                                                                |
|                       | NETosis                                    |                                                                                          |                                                                                                |
| Idebenone              | Antioxidant that protects cells             | Inhibits spontaneous NETosis in SLE LDNs but not SLE HDNs in vitro                        | Reduced disease activity and organ damage in lupus mouse models                               |
|                       | against ROS toxicity, improves mitochondrial|                                                                                          |                                                                                                |
|                       | physiology                                 |                                                                                          |                                                                                                |
| Metformin              | Unknown                                    | Decreases NET-DNA and NET-mtDNA from healthy donor HDNs in vitro                          | Open-label study showed reduced SLE flares and steroid-sparing effect                         |
|                       |                                            |                                                                                          |                                                                                                |
| N-acetylcysteine       | Free radical scavenger                     | Inhibits NETosis and free radical formation from healthy donor HDNs in vitro              | Well tolerated in phase I study in 36 SLE patients, with reduction in ADHDF Self-Report Scale scores |
|                       |                                            |                                                                                          |                                                                                                |
| Tofacitinib            | JAK1 and JAK3 inhibitor                     | Decreases NETosis in bone marrow HDNs obtained from MLR/lpr mice treated with tofacitinib | Well tolerated in a phase Ib/Ila study in 30 SLE patients, with reduction in circulating LDNs in tofacitinib-treated group |
|                       |                                            |                                                                                          |                                                                                                |
| Rituximab (followed by | Rituximab: monoclonal antibody against      | Decreases spontaneous NETosis in SLE HDNs ex vivo by reducing autoantibodies              | Rituximab followed by belimumab was safe in a phase II study, with clinical responses in patients with severe refractory SLE |
| belimumab)             | CD20; belimumab: monoclonal antibody against|                                                                                          |                                                                                                |
|                       | BAFF                                       |                                                                                          |                                                                                                |
| Vitamin D              | Unknown                                    | 1,25(OH),D, decreases NETosis in SLE HDNs in vitro                                        | Meta-analysis of RCTs showed vitamin D supplementation in SLE is safe and may improve fatigue |

* HDNs = high-density neutrophils; ANCA = antineutrophil cytoplasmic antibody; ADHD = attention deficit hyperactivity disorder; RCTs = randomized controlled trials (see Table 1 for other definitions).
idiebenone, inhibits NET formation and improves endothelial function in the MRL/pr murine model of SLE (65). Collectively, these data suggest that LDNs contribute to the excess cardiovascular risk in SLE and that targeting mitochondrial dysfunction or LDNs directly may be a potential treatment strategy.

**LDNs, cutaneous lupus, and lupus nephritis.** Netting neutrophils have been observed in biopsy samples from patients with cutaneous LE and lupus nephritis (60,78,79). The majority of SLE patients with elevated levels of LDNs display clinical skin manifestations, including vasculitis (26). Furthermore, skin biopsies from SLE patients with several forms of cutaneous LE revealed neutrophil infiltration and the presence of NET-DNA (60). Similarly, lupus nephritis has also been associated with impaired NET degradation, and NET-DNA has been observed in kidney biopsy samples from lupus nephritis patients (80). The presence of NET-mtDNA may also suggest increased LDN activity specifically (60,79). Given the importance of the findings of these few studies, further investigations into the functional role of neutrophils in SLE are required.

**Therapeutic targeting of LDNs in SLE**

LDNs represent a novel therapeutic target in SLE. Identification of the pathogenic LDN subset may facilitate development of drugs that target selective neutrophil populations while preserving critical aspects of neutrophil-mediated host defense (81). Medications that target key events in NET formation in LDNs or promote NET clearance may provide novel therapeutic strategies in SLE. These include medications already in use for treatment of SLE, as well as novel agents under investigation (Table 3).

**Conclusions**

Neutrophils play a fundamental role in protection against invading pathogens, but overactivity is associated with prolonged inflammation and tissue destruction. The discovery that they fractionate with the PBMC layer in SLE revolutionized concepts pertaining to their role in disease. The neutrophil-related gene signatures in PBMCs have been associated with common comorbidities of SLE, including cardiovascular disease and lupus nephritis (76,82–84), suggesting their critical role in pathogenesis. The physical reasons as to why the LDNs fractionate in this layer remains a target of investigation. The parallel emergence of LDNs and PMN-MDSCs has complicated the field, given their similar phenotypes and densities (85). However, their different functional roles in immune suppression and activation demonstrate that they are not the same.

So far, findings indicate that LDNs are a heterogeneous population, often with a large proportion of immature cells. There are no definitive markers to identify this population for in-depth characterization. Therefore, isolating LDNs remains a multistep and lengthy process, which limits what can be done because of the rapid apoptosis occurring ex vivo. An emerging area of research will seek to understand the interplay of LDNs, NETosis, and the adaptive immune system, based on existing data showing that LDNs can regulate T cell responses (16). While much has yet to be characterized, targeting LDNs in SLE remains a promising area for novel therapeutic intervention.

**AUTHOR CONTRIBUTIONS**

All authors drafted the article, revised it critically for important intellectual content, and approved the final version to be published.

**REFERENCES**

1. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990;29:185–8.
2. Margery-Muir AA, Bundell C, Nelson D, Groth DM, Wetherall JD. Gender balance in patients with systemic lupus erythematosus [review]. Autoimmun Rev 2017;16:258–68.
3. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:1152–9.
4. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011;3:73ra19.
5. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease [review]. Autoimmun Rev 2012;11:754–65.
6. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus [review]. Immunity 2001;15:397–408.
7. Scharer CD, Blalock EL, Mi T, Barwick BG, Jeness KA, Deguchi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nat Immunol 2019;20:1071–82.
8. Singh N, Traisak P, Martin KA, Kaplan MJ, Cohen PL, Denny MF. Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus. Arthritis Res Ther 2014;16:R165.
9. Vaughn SE, Kottyan LC, Munroe ME, Harley JB. Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways [review]. J Leukoc Biol 2012;92:577–91.
10. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994;1:219–29.
11. Ghodke-Puranik Y, Niwold T. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumatol 2013;8:10.2217/rhe.13.58.
12. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE [review]. Nat Rev Rheumatol 2010;6:317–25.
13. Dorner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 2011;363:187–97.
14. Blanco F, Kalsi J, Isenberg DA. Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases. Clin Exp Immunol 1991;86:66–70.
15. Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol 2015;16:755–65.
16. Knight JS, Kaplan MJ. Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis [review]. Curr Opin Rheumatol 2012;24:441–50.
17. Wallmán U, Letz M, Hermann M, Angermuller S, Kalden JR, Winkler TH. The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci U S A 2005;102:9258–63.
18. Ronnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019;6:e000270.
19. Preble OT, Black RJ, Friedman RM, Kliepfl JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429–31.
20. Bennett L, Palucika AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711–23.

Crow MK. Type I interferon in the pathogenesis of lupus [review]. J Immunol 2014;192:5459–68.

22. Corbridge NW, Wu Q, Yang P, Luo B, Liu S, Li J, et al. Cutting edge: intracellular IFN-β and distinct type I IFN expression patterns in circulating systemic lupus erythematosus B cells. J Immunol 2018;201:2203–8.
23. Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon α. Ann Rheum Dis 2018;77:1653–64.
24. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanas AD, Richez C, et al. Trial of anvfrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211–21.
25. Decker P. Neutrophils and interferon-α-producing cells: who produces interferon in lupus? Arthritis Res Ther 2011;13:118.
26. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010;184:3284–97.

Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, de Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med 2016;22:146–53.
28. Evrard M, Kwok IW, Chong SZ, Teng KW, Becht E, Chen J, et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. J Immunol 2018;148:3864–79.e8.
29. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532–5.

Ng LG, Ostuni R, Hidalgo A. Heterogeneity of neutrophils [review]. Nat Rev Immunol 2019;19:255–65.
31. Pillinger MH, Abramson SB. The neutrophil in rheumatoid arthritis [review]. Rheum Dis Clin North Am 1995;21:691–714.
32. Ravetch JV, Kinet JP. Fc receptors [review]. Annu Rev Immunol 2019;10:1958.
33. Wang Y, Jonsson F. Expression, role, and regulation of neutrophil Fcy receptors [review]. Front Immunol 2019;10:1958.
34. Van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications [review]. Immunol Today 1993;14:215–21.
35. Camous L, Roumenina L, Bigot S, Brachemi S, Fremeaux-Bacchi V, Lesavre P, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 2011;117:1340–9.
36. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JA, et al. In vivo labeling with [3H]H2O reveals a human neutrophil lifespan of 5.4 days. Blood 2010;116:625–7.
37. Lahoz-Beneytez J, Elemans M, Zhang Y, Ahmed R, Salam A, Block M, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood 2016;127:4341–8.
38. Thibebont N, Wright HL, Edwards SW, Witko-Sarsat V. Human neutrophils in autoimmunity. Semin Immunol 2016;28:159–73.
39. Kaplan MJ. Role of neutrophils in systemic autoimmunity diseases [review]. Arthritis Res Ther 2013;15:219.
40. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE [review]. Nat Rev Rheumatol 2011;7:691–9.
41. Chakravarti A, Rusu D, Flamand N, Borgeat P, Poubelle PE. Reprogramming of a subpopulation of human blood neutrophils by prolonged exposure to cytokines. Lab Invest 2009;89:1084–99.
42. Hacbarth E, Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum 1986;29:1334–42.
43. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences [review]. Cell Mol Life Sci 2013;70:3813–27.
44. Schmiegel J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T cell function in advanced cancer patients. Cancer Res 2001;61:4756–60.
45. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553–60.
46. Marini O, Costa S, Bevilacqua D, Calzetti F, Tamassia N, Spina C, et al. Mature CD101+ and immature CD10+ neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood 2017;129:1343–56.
47. Rahman S, Sagar D, Hanna RN, Lightfoot YL, Mistry P, Smith CK, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis 2019;78:957–66.
48. Grayson PC, Carmona-Rivera C, Xu L, Lim N, Gao Z, Asare AL, et al. Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol 2015;67:1922–32.
49. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490–500.
50. Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Núñez-Alvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol 2015;67:2990–3003.
51. Van den Hoogen LL, Fritsch-Stork RD, van Roon JA, Radstake TR. Reprogramming of a subpopulation of human blood neutrophils by prolonged exposure to cytokines. Lab Invest 2009;89:1084–99.
52. Teague HL, Varghese NJ, Tsoi LC, Dey AK, Garshick MS, Silverman JI, et al. Neutrophil subsets, platelets, and vascular disease in psoriasis. JACC Basic Transl Sci 2019;4:1–14.
53. Zhang S, Shen H, Shu X, Peng Q, Wang G. Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. Mod Rheumatol 2017;27:122–9.
54. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity [review]. Semin Immunopathol 2013;35:455–63.
55. Lakschevitz FS, Hassanpour S, Rubin A, Fine N, Sun C, Giogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res 2016;342:200–9.

56. Mistry P, Nakabo S, O’Neil L, Goel RR, Jiang K, Carmona-Rivera C, et al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A 2019;116:25222–8.

57. Srivinas US, Tan BW, Velayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer [review]. Redox Biol 2018;25:101084.

58. Lightfoot YL, Blanco LP, Kaplan MJ. Metabolic abnormalities and oxidative stress in lupus. Curr Opin Rheumatol 2017;29:442–9.

59. Coit P, Lalaverthi S, Ognenovski M, Zhao W, Haani S, Wren JD, et al. Epigenic profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J Autoimmun 2015;58:59–66.

60. Villanueva E, Lalaverthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538–52.

61. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther 2010;12 Suppl 1:S1.

62. Lood C, Arve S, Ledbetter J, Elkon KB. TLR7/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcgRIIA. J Exp Med 2017;214:2103–19.

63. Gupta S, Chan DW, Zaal KJ, Kaplan MJ. A high-throughput real-time imaging technique to quantify NETosis and distinguish mechanisms of cell death in human neutrophils. J Immunol 2018;200:869–79.

64. Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting [review]. Trends Mol Med 2016;22:230–41.

65. Blanco LP, Pedersen HL, Wang X, Lightfoot YL, Seto N, Carmona-Rivera C, et al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus patients compared to systemic lupus erythematosus. Cell 2016;165:551–65.

66. Kim J, Gupta R, Blanco LP, Yang S, Shiteiner-Kuzmine A, Wang K, et al. VDAC oligomers form mitochondrial pores to release mtDNA and promote lupus-like disease. Science 2019;366:1531–6.

67. Kahlenberg JM, Carmona-Rivera C, Smith OK, Kaplan MJ. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013;190:1217–26.

68. Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus. Front Immunol 2018;9:1250.

69. Van Dam LS, Kraaij T, Kamerling SW, Bakker JA, Scherer UH, Rabelin T, et al. Intrinsically distinct role of neutrophil extracellular trap activation in antineutrophil cytoplasmic antibody-associated vasculitis compared to systemic lupus erythematosus. Arthritis Rheumatol 2017;71:2047–68.

70. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425.

71. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018;19:108–19.

72. Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Morny S, Alecia-Torres K, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 2016;1:aaf8943.

73. Lewandowski LB, Kaplan MJ. Update on cardiovascular disease in lupus [review]. Curr Opin Rheumatol 2016;28:468–76.

74. Yu HH, Chen PC, Yang YH, Wang LC, Lee JH, Lin YT, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis 2015;243:11–8.

75. Laclaustra M, Frangi AF, Frangi AG, Casaonvajas JA, Cia P. Association of endothelial function and vascular data with LDL-c and HDL-c in a homogeneous population of middle-aged, healthy military men: evidence for a critical role of optimal lipid levels. Int J Cardiol 2008;125:376–82.

76. Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI INSIGHT 2018;3:e99276.

77. Smith CK, Vivekanandan-Giri A, Tang C, Knight JS, Mathew A, Padilla RL, et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol 2014;66:2532–44.

78. Madhusoodanan J. Core concept: role player or cellular rubbish? Biologists debate the function of neutrophil extracellular traps. Proc Natl Acad Sci U S A 2017;114:13309–11.

79. Wang H, Li T, Chen S, Gu Y, Ye S. Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol 2015;67:3190–200.

80. Hakkim A, Fumroh BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010;107:9813–8.

81. Grayson PC, Schauer C, Herrmann M, Kaplan MJ. Neutrophils as in-vigorated targets in rheumatic diseases [review]. Arthritis Rheumatol 2016;68:2071–82.

82. Jourde-Chiche N, Whalen E, Gondouin B, Speake C, Gersuk V, Dussol B, et al. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology 2017;56:477–87.

83. Banchereau J, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:551–65.

84. Toro-Dominguez D, Martorell-Marugan J, Goldman D, Petri M, Carmona-Saez P,ALARCON-RUELME ME. Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis Rheumatol 2018;70:2025–35.

85. Moses K, Brandau S. Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol 2016;28:187–96.